ClinicalTrials.gg
CompletedNCT01743729Updated Jun 23, 2021Results posted

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

A Phase 3 interventional study of Lifitegrast and Placebo in Dry Eye Disease, sponsored by Shire. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-23.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
Largest of 22
720 · median 38
Started
2012
with 1 other
Phase 3
5 of 22
none open now
Registered
4th of 22
by date
Lead sponsor
5 of 22
Shire

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one has the largest enrollment, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 4th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • SAR 1118
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to read, sign and date the and HIPAA documents
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age
  • Patient-reported history of dry eye in both eyes
  • A negative urine pregnancy test if female of and must use adequate throughout the study period
  • Artificial tear use within the past 30 days

Exclusion criteria

Exclusion Criteria:

  • Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
  • Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the duration of the study
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of immunodeficiency disorder, positive , , C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
  • Use of any prohibited medications at any time during the study unless otherwise specified
  • Any significant illness that could interfere with study parameters
  • History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to first visit, and/or any other ocular surgical procedure within 12 months prior to first visit; or any scheduled ocular surgical procedure during the study period.
  • Known history of alcohol and/or drug abuse
  • Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    Lifitegrast

    Lifitegrast Ophthalmic Solution (5.0%)

    Drug: Lifitegrast

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lifitegrast Ophthalmic Solution 5.0%

    Also known as: SAR 1118

  • DrugPlacebo

    Placebo for Lifitegrast Ophthalmic Solution 5.0%

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84

    Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=few/rare punctate lesions; 2=discrete and countable lesions; 3=lesions too numerous to count, but not coalescent; 4=coalescent) with 0.5 point increments, and lower scores indicate improvement. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

    Time frame: Baseline to Day 84

  2. Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84

    Eye dryness score was assessed on a visual analogue scale (a 7-item \[burning/stinging, itching, foreign body sensation, eye discomfort, eye dryness, photophobia, and pain\], participant-reported, symptom index) with scores ranging from 0 to 100 (0=no discomfort; 100=maximal discomfort) and lower scores indicate a better outcome.

    Time frame: Baseline to Day 84

07

Results

Posted Feb 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneLifitegrastPlacebo
Started358360
Completed321348
Not completed3712

Outcome measures

PrimaryChange From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84

Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining; 1=few/rare punctate lesions; 2=discrete and countable lesions; 3=lesions too numerous to count, but not coalescent; 4=coalescent) with 0.5 point increments, and lower scores indicate improvement. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

Time frame:
Baseline to Day 84
Reported as:
Mean · units on a scale
Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84
units on a scaleLifitegrastPlacebo
Baseline2.39 ± 0.7632.40 ± 0.722
Change from Baseline to Day 84-0.73 ± 0.926-0.71 ± 0.943
Statistical analysis
  • Lifitegrast vs Placebo · ANCOVA · p = 0.6186 · Treatment effect: 0.03 · 95% CI -0.10 to 0.17
PrimaryChange From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84

Eye dryness score was assessed on a visual analogue scale (a 7-item \[burning/stinging, itching, foreign body sensation, eye discomfort, eye dryness, photophobia, and pain\], participant-reported, symptom index) with scores ranging from 0 to 100 (0=no discomfort; 100=maximal discomfort) and lower scores indicate a better outcome.

Time frame:
Baseline to Day 84
Reported as:
Mean · units on a scale
Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84
units on a scaleLifitegrastPlacebo
Baseline69.68 ± 16.95469.22 ± 16.761
Change from Baseline to Day 84-35.30 ± 28.400-22.75 ± 28.600
Statistical analysis
  • Lifitegrast vs Placebo · ANCOVA · p = <0.0001 · Treatment effect: 12.61 · 95% CI 8.51 to 16.70

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lifitegrast—3/359 (0.8%)102/359 (28.4%)
Placebo—4/359 (1.1%)30/359 (8.4%)
Most frequent serious events
Most frequent serious events
EventLifitegrastPlacebo
VertigoEar and labyrinth disorders1/3590/359
Thyrotoxic crisisEndocrine disorders1/3590/359
Colitis ischaemicGastrointestinal disorders0/3591/359
OsteoarthritisMusculoskeletal and connective tissue disorders0/3591/359
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3591/359
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3590/359
Cerebrovascular accidentNervous system disorders0/3591/359
Most frequent other events
Most frequent other events
EventLifitegrastPlacebo
DysgeusiaNervous system disorders58/3591/359
Instillation site irritationGeneral disorders28/3595/359
Instillation site reactionGeneral disorders25/3594/359
Visual acuity reducedEye disorders18/35923/359

Baseline characteristics

Randomized population.

Age, Continuous
Age, Continuous(years)LifitegrastPlaceboTotal
Mean58.7 ± 13.9358.9 ± 14.2658.8 ± 14.09
Sex: Female, Male
Sex: Female, Male(Participants)LifitegrastPlaceboTotal
Female285265550
Male7395168
08

Study locations

31 sites
  • OPUS-2 Investigational Site
    Artesia, California 90701, United States
  • OPUS-2 Investigational Site
    Hemet, California 92545, United States
  • OPUS-2 Investigational Site
    Lancaster, California 93534, United States
  • OPUS-2 Investigational Site
    Mission Hills, California 91345, United States
  • OPUS-2 Investigational Site
    Montebello, California 90640, United States
  • OPUS-2 Investigational Site
    Newport Beach, California 92663, United States
  • OPUS-2 Investigational Site
    Petaluma, California 94954, United States
  • OPUS-2 Investigational SIte
    Rancho Cordova, California 95670, United States
  • OPUS-2 Investigational Site
    Danbury, Connecticut 06810, United States
  • OPUS-2 Investigational Site
    Fort Myers, Florida 33901, United States
  • OPUS-2 Investigational Site
    Hoffman Estates, Illinois 60169, United States
  • OPUS-2 Investigational Site
    Indianapolis, Indiana 46260, United States
  • OPUS-2 Investigational Site
    New Albany, Indiana 47150, United States
  • OPUS-2 Investigational Site
    Lexington, Kentucky 40509, United States
  • OPUS-2 Investigational Site
    Saint Paul, Minnesota 55082, United States
  • OPUS-2 Investigational Site
    Chesterfield, Missouri 63017, United States
  • OPUS-2 Investigational Site
    Des Peres, Missouri 63131, United States
  • OPUS-2 Investigational Site
    Independence, Missouri 64055, United States
  • OPUS-2 Investigational Site
    Kansas City, Missouri 64111, United States
  • OPUS-2 Investigational Site
    Washington, Missouri 63090, United States
  • OPUS-2 Investigational Site
    New York, New York 10016, United States
  • OPUS-2 Investigational Site
    New York, New York 10036, United States
  • OPUS-2 Investigational Site
    Wantagh, New York 11793, United States
  • OPUS-2 Investigational Site
    Cleveland, Ohio 44115, United States
  • OPUS-2 Investigational Site
    Philadelphia, Pennsylvania 19148, United States
  • OPUS-2 Investigational Site
    Houston, Texas 77034, United States
  • OPUS-2 Investigational Site
    Houston, Texas 77055, United States
  • OPUS-2 Investigational Site
    League City, Texas 77573, United States
  • OPUS-2 Investigational Site
    San Antonio, Texas 78209, United States
  • OPUS-2 Investigational Site
    San Antonio, Texas 78229, United States
  • OPUS-2 Investigational Site
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11. PubMed 26365210 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Oct 2013, 9 months.

Results were first posted in Feb 2017, 3 years 4 months after primary completion. A results delay was requested in Jan 2014.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 9 months is close to that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2012
First posted
Dec 6, 2012
StartActual
Dec 7, 2012
Primary completionActual
Oct 1, 2013
CompletionActual
Oct 1, 2013
Results delay requested
Jan 15, 2014
Results first posted
Feb 24, 2017
Last update
Jun 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01743729
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Dec 7, 2012
Primary completion
Oct 1, 2013
Completion
Oct 1, 2013
Results posted
Feb 24, 2017
Last update
Jun 23, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion